These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22054301)

  • 1. Kinetic and mechanistic insight into the thermodynamic degradation of saxagliptin.
    Jones GS; Savage SA; Ivy S; Benitez PL; Ramirez A
    J Org Chem; 2011 Dec; 76(24):10332-7. PubMed ID: 22054301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin.
    Dong J; Gong Y; Liu J; Chen X; Wen X; Sun H
    Bioorg Med Chem; 2014 Feb; 22(4):1383-93. PubMed ID: 24457090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saxagliptin: a new drug for the treatment of type 2 diabetes.
    Thareja S; Aggarwal S; Malla P; Haksar D; Bhardwaj TR; Kumar M
    Mini Rev Med Chem; 2010 Jul; 10(8):759-65. PubMed ID: 20402634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
    Nabeno M; Akahoshi F; Kishida H; Miyaguchi I; Tanaka Y; Ishii S; Kadowaki T
    Biochem Biophys Res Commun; 2013 May; 434(2):191-6. PubMed ID: 23501107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118).
    Kim YB; Kopcho LM; Kirby MS; Hamann LG; Weigelt CA; Metzler WJ; Marcinkeviciene J
    Arch Biochem Biophys; 2006 Jan; 445(1):9-18. PubMed ID: 16364232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications.
    Gupta A; Jacobson GA; Burgess JR; Jelinek HF; Nichols DS; Narkowicz CK; Al-Aubaidy HA
    Biochem Biophys Res Commun; 2018 Sep; 503(1):21-25. PubMed ID: 29698678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation.
    Metzler WJ; Yanchunas J; Weigelt C; Kish K; Klei HE; Xie D; Zhang Y; Corbett M; Tamura JK; He B; Hamann LG; Kirby MS; Marcinkeviciene J
    Protein Sci; 2008 Feb; 17(2):240-50. PubMed ID: 18227430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibition prevents cell death via extrinsic and intrinsic apoptotic pathways in rat pancreas with insulin resistance.
    Nephan G; Coskun ZM; Bolkent S
    Cell Biochem Funct; 2018 Jun; 36(4):212-220. PubMed ID: 29748970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saxagliptin efficacy.
    Valiquette G
    Diabetes Obes Metab; 2010 Aug; 12(8):734; author reply 735. PubMed ID: 20590752
    [No Abstract]   [Full Text] [Related]  

  • 12. Saxagliptin and tuberculosis.
    Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of dipeptidyl peptidase IV (DPP-IV) by tryptophan containing dipeptides.
    Nongonierma AB; Fitzgerald RJ
    Food Funct; 2013 Dec; 4(12):1843-9. PubMed ID: 24193022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
    Borja-Hart NL; Whalen KL
    Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovering novel α-aminoacyl-containing proline derivatives with potent and selective inhibitory activity against dipeptidyl peptidase IV: design, synthesis, biological evaluation, and molecular modeling.
    Zhang X; Wang J; Su M; Li Z; Li J; Li J; Liu H
    Chem Biol Drug Des; 2012 Dec; 80(6):843-52. PubMed ID: 22726613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a rapid UPLC-MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study.
    Gao JW; Yuan YM; Lu YS; Yao MC
    Biomed Chromatogr; 2012 Dec; 26(12):1482-7. PubMed ID: 22334441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
    Schwartz SL
    Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
    Patel CG; Kornhauser D; Vachharajani N; Komoroski B; Brenner E; Handschuh del Corral M; Li L; Boulton DW
    Diabetes Obes Metab; 2011 Jul; 13(7):604-14. PubMed ID: 21332626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
    Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
    Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
    Prescrire Int; 2011 Feb; 20(113):33-7. PubMed ID: 21488586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.